Navigation Links
Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
Date:12/6/2007

Company to Hold Conference Call on Monday, December 10, 2007

NEW HAVEN, Conn., Dec. 6 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (Nasdaq: VION) today announced that preliminary data from its pivotal Phase II trial of Cloretazine(R) (VNP40101M) in elderly patients with de novo acute myelogenous leukemia (AML) would be presented in a poster at the 2007 American Society of Hematology Annual Meeting in Atlanta, Georgia on Saturday, December 8, 2007.

The poster presentation (#71-1) will be at the Georgia World Conference Center, Hall B4, from 9:00 a.m. to 7:30 p.m. Poster authors will be available from 5:30 p.m. to 7:30 p.m. at the poster. A copy of the poster will be available on Vion Pharmaceuticals' website, http://www.vionpharm.com, on Saturday, December 8, 2007 at 9:00 a.m. Eastern Time.

A press release related to the poster will be issued on Monday, December 10, 2007 at 7:30 a.m. Eastern Time. The Company also announced that it would hold a conference call to discuss the poster on Monday, December 10, 2007. The call will begin at 9:00 a.m. Eastern Time.

To participate in the conference call, please dial (866) 356-4123 in the U.S. ((617) 597-5393 for international callers) at least 15 minutes before the start of the call. When prompted for a pass code, please enter 16444471.

An audio webcast of the call will be accessible at http://www.vionpharm.com. Those who wish to listen to the conference call on the Web should visit the Investor Relations section of the Company's website at least 15 minutes prior to the event broadcast, and follow the instructions provided to a
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2008)..., Nov. 25 Poniard,Pharm...tical company focused on,innovative oncology ther...strategic alternatives for its preclinical researc... its resources on the clinical development of pico...t the initial commercialization of,picoplatin in ...
(Date:11/25/2008)...ire-FirstCall/ -- CardioVascular,BioTherapeutics,...that it has,dosed the first patient in North Amer...rial to treat patients with severe coronary heart ...t of CORonary heart Disease) trial will include,f...oses in approximately 120,patients with severe co...
(Date:11/24/2008)...PRNewswire-FirstCall/ -- Leaders of Schering-Ploug...ate for investors on the company,s research pipeli...hat includes 46 new entities in clinical trials or...dies. , , "Research and development is addi...ontinue our transformation," said Fred Hassan, cha...
(Date:11/24/2008)...day Unveils Rich Development Pipeline of Compounds...ORTH, N.J., Nov. 24 Sche...led top-line results of a long-term Phase III clin...S(TM) (asenapine) demonstrating efficacy and safet... trial, asenapine was statistically significantly ...
Breaking Medicine Technology:Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 2Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 3Hear Indiana Announces Talk Walk Run 2008 18272 1Hear Indiana Announces Talk Walk Run 2008 18272 2Hear Indiana Announces Talk Walk Run 2008 18272 3Pennsylvania Pharmacy Carve out Poses Risks for Commonwealths Neediest Citizens and Taxpayers National Organization Testifies 18270 1Pennsylvania Pharmacy Carve out Poses Risks for Commonwealths Neediest Citizens and Taxpayers National Organization Testifies 18270 2Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 1Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 2Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 3GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 1GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 2GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 3
... /PRNewswire/ -- Results of the,Option (TOcilizuma...ers) trial, the first multinational Phase III stud...ith Actemra (either 4mg/kg,or 8mg/kg) plus methotr...ant improvement in the signs and symptoms of moder...o patients treated with,placebo and methotrexate, ...
...Biotech (OMX Nordic: ACTI) presented,pre-clinical ...The,European League Against Rheumatism, <a target=...rg ) conference, June,13-16*. , "The new pre-clin...nt inhibitory effect on disease development in an,... commented Sven,Andréasson, President &...
Other Medicine Technology:Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 2Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 3Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 4Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 5New Positive Pre-clinical Data for Active Biotech's RA Project I-3D 2
(Date:12/2/2008)... Orion Health announces that the Sou...of Juneau, Alaska, has selected the Rhapsody&trade...nic health record, radiology, pharmacy, laboratory.... It also plans to extend connectivity to statewid...unization registry) and AKAIMS (an MIS and clinica...
(Date:12/2/2008)... Dec. 2 Population Serv...hensive project that could dramatically reduce the...malaria. The program will provide free artemisinin...community health workers to poor children suspecte...to treatment will be monitored to determine if it ...
(Date:12/1/2008)...es ,Asthma & Allergy Friendly, Toy Puppies to ... Much has been made of P...ily dog. But concerns about his daughter,s asthma...ew first-dad from making a decision. So, in the m...ica (AAFA) is donating 2 "asthma & allergy fri...
(Date:12/1/2008)...New research reveals that computed tomography (CT)...has the potential to screen for two diseases at on...h commonly affect adults over age 50. Results of t...ting of the Radiological Society of North America ...screening for colorectal cancer, we were able to i...
Breaking Medicine News(10 mins):Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 2Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 3Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2
...id could provide ample energy if used properly is ...rican Journal of Physiology - Endocrinology and Me...d colleagues Takeshi Hashimoto and Rajaa Hussien i...ratory add one of the last puzzle pieces to the la...
... to a report published in Geneva it was found that...research work on diseases such as AIDS and malaria... many developing countries, especially in sub-Saha...y the Global Forum for Health Research. Stephen Ma...
...cefully can sometimes be a problem especially when... facilities looms large. //Marilyn Rantz, nursing ... calls this as a slippery slope and says that ther...m getting onto this slope. Consumers say they nev...
...more number of bus drivers and conductors in India...is that of the bus conductor Ravindra Kamble (34).... conductors in the last one year have been tested ...programme was started by General Manager SS Kshatr...
Other Medicine News:Health News:Lactic acid a potent energy giver if used properly! 2
Inquiry H Steerable Catheter. Steerable atrial mapping catheter offers a variety of designs and a unique 45 offset for catheter stability. 10 to 24 electrodes, regular and large steerable curves, ina
The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures.
...or a complete line of deflectable coronary sinus (...all with the quality, reliability and precise perf...atheter technology. All of our deflectable coronar...gned and constructed to help minimize the frustrat...
Inquiry 5FR Soft HIS diagnostic catheters provide the electrophysiologist with a uniquely designed curve that allows for placement and recording in the HIS bundle. In addition, the soft tubing is des
Medicine Products: